ImmuneOncia
immuneoncia.com
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$86.4M
1 round on record
Latest round
$86.4M
Venture round · Feb 2026 · 8 mo ago
Team
201-500
employees, estimated range
Backers
1
LB Investment
The money's age
Fresh money
8 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 8
Raised a round Venture round $86.4M · CHOSUNBIZ
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Feb 2026 | $86.4M | — | CHOSUNBIZ |
Backed byfrom the funds' portfolios and accelerator catalogs
LB Investment Investors in similar startupsfunds that back the companies most like this one
backs Gordion Bioscience
backs ImpriMed, Inc.
Similar startupsby what they do, their industry and backers
Our Tumor Activated Permeability (TAP) Platform produces weakly-acidic derivatives of known oncology drugs that already work. It preserves…
We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.
Curewiki empowers you to shape better treatments by connecting you with research — safely, and always on your terms.
ZenOnco.io, India’s first integrative oncology cancer care center. Complete cancer treatment by mainstream, complementary, and alternative…
Fueled is the leading 1st-party data platform for eCommerce.
Team Oncology drug development meets computational cancer biology Many oncology targets fail in the clinic because preclinical models…
Overview
이뮨온시아. Changing the standard ofcancer treatment by bringingKorea's 1st immune-oncology drug.
News
ImmuneOncia Therapeutics, Inc. (424870.KQ) Stock Price, News, Quote & History - Yahoo Finance
Find the latest ImmuneOncia Therapeutics, Inc. (424870.KQ) stock quote, history, news and other vital information to help you with your stock trading and investing.
Read more
Report
ImmuneOncia Therapeutics and Lonza Collaborate to Manufacture Danburstotug, a PD-L1 Antibody Targeting Immuno-Oncology
Read more
Report
ImmuneOncia raises 120 billion won via rights offering to fund R&D
ImmuneOncia raises 120 billion won via rights offering to fund R&D ImmuneOncia Therapeutics, Yuhans anticancer drug research and development R&D subs
Read more
Report
ImmuneOncia Announces Interim Results from Phase 1b Clinical Trial of Next-Generation CD47 Antibody
/PRNewswire/ -- ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial of its...
Read more
Report
ImmuneOncia, Biobijou, d'Alba Global plan public offerings in South Korea
ImmuneOncia, Biobijou, dAlba Global plan public offerings in South Korea After the golden holiday, ImmuneOncia, Biobijou, and dAlba Global will condu
Read more
Report
Report
Samsung Biologics signs multi-product development and manufacturing agreement with ImmuneOncia
Samsung Biologics and ImmuneOncia Therapeutics held a signing ceremony today for a contract to develop and manufacture five candidate molecules, expanding upon the two companies' existing CDO partnership first established in 2018.. Under this extended dea
Read more
Report
Financials
Total raised
$86.4M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $86.4M | Details |